back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2024-03-01 13:35 Tx date 2024-03-01 |
$SONA
Sona Nanotech Inc. |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+110,000 vol |
535,000 | |
| Filed 2023-07-17 14:52 Tx date 2023-07-13 |
$QPT
Quest PharmaTech Inc. |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$24,000
+300,000 vol $0.08 each |
1,050,000 | |
| Filed 2023-07-11 11:14 Tx date 2023-07-10 |
$SONA
Sona Nanotech Inc. |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+150,000 vol |
425,000 | |
| Filed 2023-03-30 10:55 Tx date 2023-03-28 |
$SONA
Sona Nanotech Inc. |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$29,750
+175,000 vol $0.17 each |
275,000 | |
| Filed 2022-07-25 10:52 Tx date 2022-07-21 |
$QPT
Quest PharmaTech Inc. |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$27,000
+300,000 vol $0.09 each |
750,000 | |
| Filed 2021-12-27 12:50 Tx date 2021-12-24 |
$BIO
Biome Grow Inc. |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+500,000 vol |
1,000,000 | |
| Filed 2021-11-15 15:09 Tx date 2021-11-12 |
$SONA
Sona Nanotech Inc. |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$44,000
+100,000 vol $0.44 each |
100,000 | |
| Filed 2021-11-15 15:03 Tx date 2020-11-02 |
$SONA
Sona Nanotech Inc. |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-07-09 18:54 Tx date 2021-07-05 |
$QPT
Quest PharmaTech Inc. |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$15,000
+150,000 vol $0.10 each |
450,000 | |
| Filed 2021-07-09 18:32 Tx date 2021-07-05 |
$QPT
Quest PharmaTech Inc. |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$10,000
+100,000 vol $0.10 each |
||
| Filed 2021-07-09 18:31 Tx date 2021-07-05 |
$QPT
Quest PharmaTech Inc. |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
300,000 | ||
| Filed 2020-12-17 15:04 Tx date 2020-12-15 |
$SONA
Sona Nanotech Inc. |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Warrants
53 - Grant of warrants
|
$15,625
+12,500 vol $1.25 each |
12,500 | |
| Filed 2020-12-17 15:04 Tx date 2020-11-02 |
$SONA
Sona Nanotech Inc. |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2020-12-17 15:03 Tx date 2020-12-15 |
$SONA
Sona Nanotech Inc. |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$25,000
+25,000 vol $1.00 each |
25,000 | |
| Filed 2020-12-17 15:03 Tx date 2020-11-02 |
$SONA
Sona Nanotech Inc. |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2020-09-21 21:27 Tx date 2020-07-31 |
$BIO
Biome Grow Inc. |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+500,000 vol |
500,000 | |
| Filed 2020-09-21 21:26 Tx date 2018-10-03 |
$BIO
Biome Grow Inc. |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2020-04-02 17:56 Tx date 2020-03-30 |
$ASP
Acerus Pharmaceuticals Corporation |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$104,645
+2,315,172 vol $0.0452 each |
2,715,172 | |
| Filed 2019-11-04 10:38 Tx date 2019-11-01 |
$ASP
Acerus Pharmaceuticals Corporation |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,600
+20,000 vol $0.08 each |
61,000 | |
| Filed 2019-11-04 10:38 Tx date 2019-10-21 |
$ASP
Acerus Pharmaceuticals Corporation |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$85.00
+1,000 vol $0.085 each |
41,000 | |
| Filed 2019-03-07 Tx date 2019-03-06 |
$ASP
Acerus Pharmaceuticals Corporation |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$26,000
+200,000 vol $0.13 each |
400,000 | |
| Filed 2019-02-28 Tx date 2018-11-28 |
$ONC
Oncolytics Biotech Inc. |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units
57 - Exercise of rights
|
-5,263 vol |
||
| Filed 2019-02-28 Tx date 2018-11-28 |
$ONC
Oncolytics Biotech Inc. |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units
57 - Exercise of rights
|
-5,263 vol |
31,008 | |
| Filed 2019-01-31 Tx date 2019-01-29 |
$QPT
Quest PharmaTech Inc. |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$18,000
+100,000 vol $0.18 each |
300,000 | |
| Filed 2018-11-30 Tx date 2018-11-28 |
$ONC
Oncolytics Biotech Inc. |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
+2,267 vol |
4,688 | |
| Filed 2018-11-30 Tx date 2018-05-22 |
$ONC
Oncolytics Biotech Inc. |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units
37 - Stock split or consolidation
|
-239,178 vol |
28,137 | |
| Filed 2018-11-30 Tx date 2018-05-22 |
$ONC
Oncolytics Biotech Inc. |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Common Shares
37 - Stock split or consolidation
|
-20,579 vol |
2,421 | |
| Filed 2018-11-30 Tx date 2018-11-27 |
$ONC
Oncolytics Biotech Inc. |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units
56 - Grant of rights
|
+8,134 vol |
36,271 | |
| Filed 2018-11-30 Tx date 2018-05-22 |
$ONC
Oncolytics Biotech Inc. |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-136,449 vol |
16,051 | |
| Filed 2018-11-30 Tx date 2018-11-28 |
$ONC
Oncolytics Biotech Inc. |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units
57 - Exercise of rights
|
-5,263 vol |
31,008 | |
| Filed 2018-09-07 Tx date 2018-09-07 |
$ASP
Acerus Pharmaceuticals Corporation |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,640
+14,000 vol $0.26 each |
40,000 | |
| Filed 2018-08-31 Tx date 2018-08-30 |
$ASP
Acerus Pharmaceuticals Corporation |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$5,600
+20,000 vol $0.28 each |
26,000 | |
| Filed 2018-08-31 Tx date 2018-08-29 |
$ASP
Acerus Pharmaceuticals Corporation |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$560.00
+2,000 vol $0.28 each |
6,000 | |
| Filed 2018-08-29 Tx date 2018-08-28 |
$ASP
Acerus Pharmaceuticals Corporation |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,120
+4,000 vol $0.28 each |
4,000 | |
| Filed 2018-08-29 Tx date 2017-12-06 |
$ASP
Acerus Pharmaceuticals Corporation |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2018-01-04 Tx date 2018-01-02 |
$QPT
Quest PharmaTech Inc. |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+50,000 vol |
200,000 | |
| Filed 2017-12-13 Tx date 2017-12-12 |
$ONC
Oncolytics Biotech Inc. |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Options
52 - Expiration of options
|
$-38,850
-17,500 vol $2.22 each |
152,500 | |
| Filed 2017-12-11 Tx date 2017-12-06 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$72,000
+200,000 vol $0.36 each |
200,000 | |
| Filed 2017-12-11 Tx date 2017-12-06 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2017-12-04 Tx date 2017-12-01 |
$ONC
Oncolytics Biotech Inc. |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units
56 - Grant of rights
|
+37,729 vol |
267,315 | |
| Filed 2017-07-24 Tx date 2017-07-19 |
$QPT
Quest PharmaTech Inc. |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$22,500
+150,000 vol $0.15 each |
150,000 | |
| Filed 2017-07-24 Tx date 2017-07-13 |
$QPT
Quest PharmaTech Inc. |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2017-07-24 Tx date 2017-07-13 |
$QPT
Quest PharmaTech Inc. |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2017-01-19 Tx date 2017-01-16 |
$ONC
Oncolytics Biotech Inc. |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units
56 - Grant of rights
|
+100,000 vol |
229,586 | |
| Filed 2017-01-19 Tx date 2017-01-18 |
$ONC
Oncolytics Biotech Inc. |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Options
52 - Expiration of options
|
$-22,500
-10,000 vol $2.25 each |
170,000 | |
| Filed 2016-10-06 Tx date 2016-10-03 |
$ONC
Oncolytics Biotech Inc. |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units
56 - Grant of rights
|
+79,586 vol |
129,586 | |
| Filed 2015-12-14 Tx date 2015-12-09 |
$ONC
Oncolytics Biotech Inc. |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units
56 - Grant of rights
|
$20,000
+50,000 vol $0.40 each |
50,000 | |
| Filed 2015-12-14 Tx date 2004-04-05 |
$ONC
Oncolytics Biotech Inc. |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units
00 - Opening Balance-Initial SEDI Report
|